Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Simple Summary Androgen receptor splice variants (AR-Vs) play an important role in
prostate cancer progression, especially as a putative resistance mechanism against AR …

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form,
genetic and epigenetic adaptation, clonal selection, and evolution of the tumor …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Aberrant activation of androgen receptor (AR) signaling occurs in patients treated with AR-
targeted therapies, contributing to the development of castration-resistant prostate cancer …

Abstract Background Approximately 10–30% of men with mCRPC will test positive for AR-V7
using one of two analytically and clinically validated circulating tumor cell (CTC)-based …

Context Although a number of studies have demonstrated the importance of constitutively
active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about …

In the past five years, multiple structurally and functionally distinct androgen receptor (AR)
splice variants have been decoded and characterized. The mature transcripts for the …

Upregulation of constitutively-active androgen receptor splice variants (AR-Vs) has been
implicated in AR-driven tumor progression in castration-resistant prostate cancer. To date …

Persistent androgen receptor (AR) signalling is the main driver of prostate cancer (PCa).
Truncated isoforms of the AR called androgen receptor variants (AR-Vs) lacking the ligand …